[20210301]IN11560_2019冠状病毒疾病疫苗和辅助接种材料的Warp-Speed行动合同.pdf

上传人:任我行 文档编号:30381 上传时间:2022-06-24 发布时间:2021-03-02 格式:PDF 页数:4 大小:689.21KB
下载 相关 举报
[20210301]IN11560_2019冠状病毒疾病疫苗和辅助接种材料的Warp-Speed行动合同.pdf_第1页
第1页 / 共4页
[20210301]IN11560_2019冠状病毒疾病疫苗和辅助接种材料的Warp-Speed行动合同.pdf_第2页
第2页 / 共4页
[20210301]IN11560_2019冠状病毒疾病疫苗和辅助接种材料的Warp-Speed行动合同.pdf_第3页
第3页 / 共4页
[20210301]IN11560_2019冠状病毒疾病疫苗和辅助接种材料的Warp-Speed行动合同.pdf_第4页
第4页 / 共4页
亲,该文档总共4页,全部预览完了,如果喜欢就下载吧!
资源描述

1、CRS INSIGHT Prepared for Members and Committees of Congress INSIGHTINSIGHTi i Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials Updated March 1, 2021 Operation Warp Speed (OWS) is an interagency partnership between the Department of Health and Human Services (H

2、HS) and the Department of Defense (DOD) that coordinates federal efforts to accelerate the development, acquisition, and distribution of COVID-19 medical countermeasures. Collaborating HHS components include the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH

3、), and the Biomedical Advanced Research and Development Authority (BARDA). OWS is a Trump Administration initiative, and while the Biden Administration has indicated that the interagency response to COVID-19 will continue, it plans to restructure and rename the effort. Although the stated goals of O

4、WS include therapeutics and diagnostics, most of the money awarded to date has focused on vaccines. This Insight summarizes OWSs vaccine-related contracts, including those for ancillary vaccination materials (e.g., needles and vials). BARDA is currently supporting six vaccine candidates through fund

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告